Prostate cancer (PCa) is one of the most common non-cutaneous malignancies among men in the US, with an estimated 240,890 new cases and 33,720 deaths in 2010[@b1]. Although little is known about the etiology of the disease, accumulating evidence has demonstrated that genetic variations may play a crucial role in the carcinogenesis of PCa. For example, genome-wide association studies (GWASs) have identified more than 40 human PCa-predisposing variants, among which single nucleotide polymorphisms (SNPs) located in the 8q24 region were considered as promising biomarkers for PCa[@b2][@b3][@b4][@b5][@b6]. However, not all of those significant findings can be validated by the subsequent candidate-based studies.

Chromosomal region 8q24 has emerged recently as bona fide risk locus for multiple cancers[@b7][@b8][@b9]. Fine mapping and additional genome scans have identified three 8q24 regions (region 1: 128.54--128.62 Mb; region 2: 128.12--128.28 Mb; region 3: 128.47--128.54 Mb) that contain variants independently associated with PCa risk[@b2][@b3][@b10][@b11]. Since the 8q24 region was originally shown to confer a PCa risk in a genome wide linkage scan of 871 Icelandic men in 2006[@b8], numerous association studies have been performed to extensively explore the roles of 8q24 single nucleotide polymorphisms (SNPs) in the etiology of PCa. To date, there are about 64 variants in 8q24 investigated for the association with PCa risk, and only 20 of those variants were confirmed to be PCa risk-associated SNPs. Of those PCa risk SNP, rs1447295 C\>A in region 1, rs16901979 C\>A in region 2, and rs6983267 T\>G in region 3, have shown strong association with PCa, with respective adjusted *P* value of 4 × 10^−29^ , 1 × 10^−19^, and 1 × 10^−11^ [@b12]. Similarly, significant associations with 8q24 polymorphisms were also identified for a wide spectrum of cancers, including cancers of the breast[@b13][@b14], prostate[@b2][@b4], bladder[@b15], colon[@b16], lung[@b17], ovaries[@b18], pancreas[@b19], and brain[@b20] among different ethnicities (Asian, Caucasian, and African of Americans). Taken together, these findings have made SNPs on 8q24 of particular interest because of their potential roles in screening strategies for high-risk individuals and discovering new therapeutic targets.

The mechanisms by which 8q24 influences the course of PCa are not yet fully understood. The 8q24 region has been described as a "gene desert" since the 600-kbp gene-poor region appears to have little or no transcriptional activity. Nevertheless, several lines of evidence has suggested that 8q24 may play an active role in PCa carcinogenesis. First, 8q24 is a highly conserved genomic region. Second, *POU5F1P1*, an important gene on 8q24, encodes a weak transcriptional activator that may contribute to carcinogenesis[@b21]. Third, recent studies have shown that the activity of the nearby oncogene *MYC* is associated with 8q24[@b4][@b22][@b23][@b24].

Although PCa carcinogenesis has been found to be associated with hereditary background, increasing molecular epidemiology studies have presented conflicting results on the association between 8q24 SNPs and PCa risk, which may be partially attributable to various sample sizes, different genetic backgrounds, and heterogeneous inclusion criteria among studies. With this in mind, we carried out the current meta-analysis to provide a quality assessment of the association of the most frequently analyzed 8q24 SNPs (i.e., rs1447295 C\>A in region1, rs16901979 C\>A in region2, and rs6983267 T\>G in region3) with PCa risk.

Results
=======

Eligible studies
----------------

Based on the inclusion criteria, 22 eligible articles consisting of 44 studies were included in this meta-analysis[@b1][@b12][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40]. The sample sizes of those studies ranged from 103 to 24454. Of those articles, 9 and 13 were categorized as high and low quality, respectively, using methods described in the Methods section. Literature search and study selection yielded 20 studies for rs1447295 C\>A analysis, which were performed among Caucasians (10 studies), Asians (7 studies), and Africa-Americans (3 studies). A total of 7 eligible studies were retrieved for rs16901979 C\>A analysis with 3, 3, and 1 studies conducted in these three ethnic groups, respectively. Moreover, of 17 studies eligible for rs6983267 T\>G analysis, there were 9, 6, and 2 carried out in these three ethnic groups, respectively. Other details were shown in [Table 1](#t1){ref-type="table"}. Genotype frequency distributions of studied SNPs in all of the control populations were agreed with HWE.

Quantitative synthesis
----------------------

A total 20 eligible studies were pooled together to evaluate the association between 8q24 rs1447295 C\>A and PCa risk, with 20184 cases and 20439 controls. Pooled risk estimates indicated the significant associations of rs1447295 C\>A with increased PCa risk under homozygous (OR= 1.39; 95% CI= 1.01--1.91, *P *= 0.042), heterozygous (OR= 1.26, 95% CI= 1.09--1.45, *P *= 0.002), dominant models (OR= 2.46, 95% CI= 1.89--3.20, *P *= 0.000), and alleles comparison (OR= 1.23, 95% CI= 1.09--1.40, *P *= 0.001); intriguingly, the direction of the association was reversed under recessive genetic models (OR= 0.51, 95% CI= 0.39--0.67, *P *= 0.001) as shown in [Table 2](#t2){ref-type="table"}. Moreover, there were 7 eligible studies available for 8q24 rs16901979 C\>A analysis, consisting of 1850 cases and 2090 controls. We found that carrier of AA, AC, or combined carriers of AA/AC risk genotypes had an OR of 1.71 (homozygous: 95% CI= 1.36--2.16, *P *= 0.000), 1.31 (heterozygous 95% CI= 1.12--1.53, *P *= 0.001), or 1.39 (dominant: 95% CI= 1.20--1.61, *P *= 0.000) for developing prostate cancer, respectively, compared with those with CC genotype. And OR of alleles comparison (C vs. A) for the association was 1.31 (95% CI= 1.18--1.46, *P *= 0.000). For 8q24 rs6983267 T\>G analysis, a total of 17 studies comprising 12233 cases and 7582 controls were incorporated into the meta-analysis. Pooled analysis observed significant associations between increased PCa risk and the variant of interest under homozygous (OR= 1.44; 95% CI= 1.31--1.58, *P *= 0.000), heterozygous (OR= 1.19, 95% CI= 1.10--1.29, *P *= 0.000), recessive (OR= 1.26, 95% CI= 1.18--1.36, *P *= 0.000), and alleles comparison (OR= 1.19, 95% CI= 1.14--1.25, *P *= 0.000).

Stratification analysis
-----------------------

In the stratification analyses, subgroups with less than three studies were excluded from further analysis because of small number of subgroups would likely lead to a false association. In the current meta-analysis, positive associations were found among most of the remaining subgroups for each of the three 8q24 SNPs. Briefly, the associations of rs1447295 C\>A polymorphism and PCa risk were observed among Asians populations under the all assumed genetic comparisons, among Caucasians under recessive and dominant models, but not among Africa-Americans. Similarly, stratified analysis by source of control found that rs1447295 C\>A showed significant association with PCa risk for PB subgroup under all genetic models, while the association was only detected under recessive, dominant model, and allele comparison for HB subgroup. Moreover, the associations were observed for both low and high quality subgroups.

As shown in [Table 2](#t2){ref-type="table"}, due to the limited number of study, stratification analysis for rs1601979 C\>A polymorphism was not conducted among Caucasians and PB studies. The significant risk effects of rs1601979 C\>A polymorphism on PCa risk were consistently observed under the most of assumed genetic comparisons for Africa-Americans, hospital-based studies, and studies with high quality score. The effects were also existed among Asians and studies with low quality score, with fewer genetic models detecting the significance. We then compared the strength of the associations within the subgroups, the association with larger OR and smaller *P* value was considered as more prominent than others. Interestingly, the association between PCa and rs16901979 was more prominent among Africa-Americans than Asians under most of genetic models (e.g. Africa-Americans with homozygous OR= 1.91, 95% CI= 1.44--2.55, *P *= 0.000; heterozygous OR= 1.41 (1.10--1.80), *P *= 0.000; dominant OR= 1.56, 95% CI= 1.24--1.96, *P *= 0.000; and allele comparison OR= 1.40, 95% CI= 1.21--1.62, *P *= 0.000. In contrast, Asians with recessive OR= 1.65, 95% CI= 1.13--2.41), *P *= 0.000; and allele comparison OR= 1.17, 95% CI= 1.00--1.38, *P *= 0.053) . Moreover, stratified analyses observed significantly increased PCa risk associated with rs6983267 T\>G polymorphism among all subgroups defined by ethnicity, source of control, and quality score. Likewise, rs6983267 T\>G seemed to confer a higher Pca risk in Caucasians than Asians (homozygous OR= 1.47, 95% CI= 1.33--1.64, *P *= 0.000 vs. OR= 1.33, 95% CI= 1.08--1.62, *P *= 0.006; Allele comparison OR= 1.21, 95% CI= 1.15--1.27, *P *= 0.000 vs. Allele comparison OR= 1.14, 95% CI= 1.03--1.25, *P *= 0.01).

In the current meta-analysis, a high level of heterogeneity was detected in the pooled analysis for rs1447295 C\>A. However, the heterogeneity decreased in the stratified analysis by ethnicity, indicating that ethnicity might be a source of heterogeneity. Moreover, the between-study heterogeneity was detected among several subgroups for each of studied SNPs. However, leave-one-out sensitivity analyses suggested that no single study substantially altered the pooled ORs of any SNP of interest (data not shown), suggesting the stability of this meta-analysis. Finally, the FPRP values for all significant findings at different prior probability levels were summarized in [Table 3](#t3){ref-type="table"}. With the assumption of prior probability of 0.01, the association with rs1447295 C\>A was noteworthy for Asians, population-based studies and high quality studies (FPRP range: 0.010--0.144, 0.010--0.022, 0.010--0.014, respectively) under the assumed comparisons. Moreover, the association between PCa and rs16901979 C\>A among Africa-American (FPRP: 0.026) under dominant and allele comparison was considered noteworthy. In term of rs6983267 T\>G, the association was noteworthy for Caucasians, population-based studies, high quality studies, low quality studies. In contrast, based on FPRP values, the rest of significant associations between 8q24 variants and PCa risk might not be deserving of attention, suggesting some possible bias or chance finding in this meta-analysis. Therefore, our findings need to be further validated in large and well-designed studies, involving different ethnicities ([Fig. 1](#f1){ref-type="fig"}).

Publication Bias Analysis
-------------------------

Publication bias was examined by Begg's funnel plots and Egger's tests across all genetic models for each of the three polymorphisms in the 8q24 region. The shape of funnel plot ([Fig. 2](#f2){ref-type="fig"}) was symmetrical, suggesting that there was no evidence of publication bias in the meta-analysis.

Discussion
==========

To the best of our knowledge, this is the largest meta-analysis to investigate the association between the selected 8q24 SNPs and PCa risk based on the candidate association studies. Up to now, more than 64 8q24SNPs have been explored for their role in PCa carcinogenesis, among which about 20 SNPs are regarded as PCa-related SNPs. However, those results were often controversial. In this meta-analysis, we evaluated the association of PCa risk with three most frequently investigated SNPs that scatter through the three regions of 8q24, respectively. We found significant associations between each of these 8q24 SNPs and PCa risk under most of the assumed comparisons, either in overall or in stratified analyses by ethnicity, source of control, and quality score. Intriguingly, stratified analyses by ethnicity revealed significant association between rs1447295 C\>A and PCa risk among Caucasians and Asians, but not Africa-Americans. The effect of polymorphism rs16901979 C\>A on PCa risk was more apparent in Africa-Americans populations when compared with Asian populations. Similarly, rs6983267 conferred a higher Pca risk among Caucasians than Asians. Although it is difficult to explain the ethnic-specific findings, the disparity in different ethnic populations is not completely surprising. Incidence rates of PCa vary internationally by over 25-fold. Developed countries in Oceania, Europe, and North American have the highest rates of PCa, while incidence in Asia is relatively low[@b41]. On the contrary, the highest prostate cancer mortality rates are recorded in African descent in the Caribbean region, which is partly explained by genetic predisposition[@b42][@b43]. Taken together, these epidemiological findings have suggested that both environmental and genetic factors may have profound impacts on PCa. Therefore, we speculated that differences in environments, genetic backgrounds, and gene-environment interaction may help to interpret the different results in the different ethnic groups. Future studies may provide some insights into the ethnic-specific findings, focusing on a difference in LD between these variants and the causal variants in each ethnic group, epistasis with other variants found in these ethnicities, or gene-environment interaction.

Moreover, although mechanisms by which 8q24 modulates the risk of PCa is poorly understood, mounting evidence from genetic association studies and fine-mapping informatics supports that 8q24 genetic variant may impart susceptibility to PCa in an ethnic-specific manner. 8q24 region is commonly subdivided into three regions on the basis of the local genetic characteristics of 8q24 and the fine-mapping study[@b11]. Region 1 (126.54--128.62 Mb) was initially identified by the original linkage and admixture studies in Icelandic families populations; and initial association studies indicated that this region might contribute to a higher incidence of PCa in Africa-American men than men of European ancestry[@b7][@b8]. Region 2 (128.14--128.28 Mb) harbors a 14-SNP haplotype that efficiently tags a relatively uncommon (2--4%) susceptibility variant in individuals of European descent, which happens to be very common (42%) in Africa-Amricans[@b2][@b10]. And region 3 (128.47--128.54 Mb) is defined as a recombination hot-spot among European Americans. There is little linkage disequilibrium among SNPs across the three regions. Although regions 1 and 3 are physically close to each other, they are separated by a recombination hotspot among individuals of European ancestry[@b2]. Hence, SNPs across all three neighboring regions seem to independently influence 8q24 signal transduction, and the combined effects of SNPs across regions closely follow a multiplicative model[@b2][@b10]. Human chromosome 8q24 contains three regions spanning 6000 kb, according to the dbSNP database (<http://www.ncbi.nlm.nih.gov/SNP>), in which more than 207 variants were reported. Twenty previously reported 8q24SNPs statistically significantly associated with PCa risk show various linkage disequilibrium (LD) with a range from low to high degree ([Fig. 3](#f3){ref-type="fig"}). These SNPs can be divided into three blocks. For example, block1 included rs698267, rs10505476, rs10505474, and rs7837328, showing LD with r^2^ values ranging from 0.28 to 0.95. Block2 consisted of rs1447295, rs4242382, rs7017300, rs11986220, rs10090154, and 7837688, with LD (r^2^) varying from 0.23 to 1.0. Additionally, rs16901979 was found in high LD of 1.0 with some polymorphisms including rs6983561, rs16901966, and rs1551512. None of the variants resides within known genes, of which there are few across the regions of 8q24. It was predicted that those risk-associated variants could affect the regulation or transcription of a causal pseudogene or gene outside the region, including proto-oncogene MYC (located approximately 260 kb telomeric to region 1), FAM84B, TCF7L2, and POU5F1[@b21][@b44], but the biological mechanisms underlying these findings remain unclear. Another speculation that may help to explain the association is that some functional polymorphisms linked to those SNPs may account for the association. However, based on current understanding, none of these variants and their respectively linked-SNPs seems to be potentially functional. Therefore, the exact mechanisms underlying the observed association of the SNPs with PCa risk need more investigations.

8q24 was considered as a gene-free region, flanked by the *FAM84B* and *MYC* genes on the centromeric and telomeric ends, respectively. Although data based on epidemiologic studies have indicated the possible association between 8q24 variants and PCa risk, little is known about the mechanisms. There are significant differences in allele frequency distribution of the three selected SNPs among different ethnic-populations, indicating these 8q24 variant(s) may modulate PCa in an ethnic-specific manner. One study suggested that variants in this region may be a part of the *cis*-regulatory enhancer element for the *MYC* gene, with a long-range physical interaction with this gene in PCa[@b4]. For example, a recent report indicated that rs6983267 displayed an altered capacity of binding of transcription factor 7-like 2 (*TCF7L2*), thereby leading to a different physical interaction with *MYC*[@b44]. However, others failed to find clear association between rs6983267 genotype and MYC expression. Therefore, more powerful studies should be performed to further investigate the function of the risk- associated SNPs.

Up to now, several meta-analyses have investigated the associations between 8q24 polymorphisms and PCa risk[@b45][@b46][@b47]. And consistent findings were observed among the previously reported meta-analyses and the present study, indicating that 8q24-rs1447295, -rs16901979, and --rs6983267 polymorphisms might confer genetic susceptibility to PCa. Additionally, this meta-analysis was the first to further explore the associations by stratification analyses (ethnicity, source of control, and quality score), as compared to others. However, although significant associations were found in the stratification analyses by ethnicity, these findings warrant further validation in large, well-designed, multiethnic case-control studies.

Finally, some limitations in the meta-analysis should be addressed. First, relatively small samples were included for the assessment, especially for rs16901979 polymorphism. Second, the controls were not uniformly defined, which might result in obscure findings. Third, there was a significant heterogeneity in different ethnic groups; the heterogeneity may be partially attributed to the difference in individuals' genetic backgrounds or the environment in which subjects live, since these genetic and environmental factors may modify the risk effects of studied SNP on cancer susceptibility. Fourth, due to inadequate information, we failed to control for possible confounders such as age, smoking, obesity, alcohol consumption, and other lifestyle risk factors, and our results were based on unadjusted estimates. Finally, the ethnic-specific effects of the studied SNPs on PCa risk were not adequately discussed due to lack of relevant publications.

In summary, this meta-analysis provided evidence of the association between 8q24 polymorphisms (i.e. rs1447295 C\>A, rs16901979 C\>A, and rs6983267 T\>G) and PCa risk, suggesting that these 8q24 variants may be a low penetrance contributor to PCa. Considering that PCa is one of genetic and geographic related malignancies, more relevant SNPs, variants, SNP-induced gene structural changes, epigenetic changes, and interactions of SNP-SNP, gene-gene, and gene-environment should be addressed in future large multicentric studies, which should lead to better, comprehensive understanding of the association between the 8q24 Polymorphisms and PC risk.

Methods
=======

Search strategy and selection criteria
--------------------------------------

A comprehensive literature search was carried out for publications investigating the association between 8q24 polymorphisms and PCa risk. We searched PubMed, Embase and China Biology Medicine (CBM) databases up to June 2014 using the following keywords, including "8q24", "variant or polymorphism", "cancer, carcinoma, or malignancy", and "prostate disease". Further limited searching strategy included "English and Chinese language publications" and "human species". Abstracts alone and unpublished articles were not considered. Moreover, the reference lists of the retrieved articles and reviews were sought manually to find relevant original articles. Eligible Studies for this meta-analysis were required to meet all of the following criteria: (i) studies on associations of at least one of 8q24 polymorphisms (rs1447295 C\>A, rs6983267 T\>G, rs16901979 C\>A) with PCa risk; (ii) enrolled patients had sporadic, primary and histologically confirmed PCa, and controls had no history of cancer or neoplasm; (iii) case-control or nested case-control studies; (iv) availability of genotype data of both case and control group to calculate the odds ratio (OR) with its 95% confidence interval (CI) and *P* value; and (v) genotype distribution in controls is complied with the Hardy-Weinberg equilibrium (HWE, *P*\>0.05). All of the included studies were candidate-based association studies. If participants in studies overlapped, only the study with the largest sample size was included in the meta-analysis. The flow chart of identification the eligible studies was shown in [Fig. 4](#f4){ref-type="fig"}, and the protocol was checked according to the PRISMA checklist (Supporting Information).

Assessment of study quality: Extended Quality Score
---------------------------------------------------

The quality of each included investigation was estimated using Extended Quality Score to limit the risk of introducing bias into meta-analyses or systematic reviews. Each article is defined as "high" or "poor" quality according to an extended-quality scale system by evaluating special characteristics of the participant groups and genotyping methods of the studies[@b48]. In this meta-analysis, two investigators appraised the quality of each investigation. If there was any disagreement, a third investigator (Jin-Hong Zhu) would mediate and a decision would be made by voting.

Data extraction
---------------

Two reviewers (Qiaoxin Li and Xia Liu) independently appraised and extracted data according to the inclusion criteria listed above. Disagreements were documented and resolved by full discussion with a third reviewer (Jin-Hong Zhu) until a consensus was reached. The following information were extracted from each eligible study: the first author's surname, year of publication, country in which study was conducted, ethnicity of participants (categorized as Caucasians, Asians, and African descents), study design, sample size, source of control, *P* value of HWE test, genotyping methods, genotype counts of case and controls for three studied SNPs, and the clinical/pathological characteristics of cases. For studies involving subjects of different ethnic groups, data were extracted and split by ethnicity.

Statistical analysis
--------------------

HWE in the control groups was assessed by the Pearson's goodness-of-fit chi-square test, with a *P* value less than 0.05 indicating derivation from HWE, and population was regarded as suitable if more than one SNP agreed with HWE. The strength of association between 8q24 polymorphisms and PCa risk was estimated by calculating odds ratios (OR) and the corresponding 95% confidence intervals (CI). For each of studied SNP, we conducted comparison of the frequency of wild (*W*) and variant (*V*) alleles between PCa cases and controls (*V* vs. *W*). Moreover, pooled ORs were calculated under the following genetic models: homozygous (*VV* vs. *WW*), heterozygous (*VW* vs. *WW*), dominant (*VV* + *VW* vs. *WW*), and recessive (*VV* vs*. VW* + *WW*) models. Stratification analyses were performed by ethnicity, source of control, and quality score, but not by tumor stage, Gleason score, and PAS levels because of the small size of the eligible studies. For each genetic model, a χ^2^-based Q-test was performed to check the presence of between-study heterogeneity across all of the comparisons at a level of significance of 0.10[@b49]. In addition, the heterogeneity was also quantified with *I*^*2*^ statistics, which is independent of the number of studies included in the meta-analysis. *I*^*2*^ lies between 0% and 100% with higher values indicating a greater heterogeneity[@b50]. The fixed-effects model was chosen to calculate the combined OR in the absence of heterogeneity. Otherwise, a random-effects model was used to estimate the pooled OR. The significance of the pooled OR was determined using the Z test. Finally, false positive report probability (FPRP) was introduced as a multiple testing for the whole significant associations. The statistical power of the current study was calculated with an FPRP threshold of 0.2 was defined as true finding, i.e., the probability of a false positive result is \<20%[@b49]. In sensitivity analysis, following the sequential exclusion of a single study at a time, the pooled estimates were recomputed to determine the stability of the results. Furthermore, potential publication bias was assessed by visual inspection of Begg's funnel plots with an asymmetry plot suggested possible publication bias[@b51]. All statistical analyses were performed using STATA statistical software (version 11.0, StataCorp, College Station, TX) and SAS version 9.1 (SAS Institute, Cary, NC). Two-sided *P* values were adopted, and *P* \<0.05 were considered statistically significant without further notification.
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![Forest plots of effect estimates for *8q24*-rs1447295 polymorphism and prostate cancer risk (AA+AC vs. CC).\
The size of the squares indicates the relative weight of each study. Weights were derived from random-effects analysis. Bars, 95% confidence interval (CI).](srep12069-f1){#f1}

![Funnel plot analysis to detect publication bias for each of the *8q24* polymorphism by homozygous model.\
(**A**) For rs1447295 polymorphism, (**B**) For rs16901979 polymorphism, and (**C**) For rs6983267 polymorphism. Each point represented an individual study for the indicated association.](srep12069-f2){#f2}

![Linkage disequilibrium in the 8q24 region for the previously reported polymorphisms.\
Linkage disequilibrium coefficients (r^2^) between SNPs in the 8q24 region between 128.12 and 128.54 Mb.](srep12069-f3){#f3}
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###### Characteristics of studies included in the current meta-analysis.

  Surname                          Year    Country        Ethnicity      Source   Genotype method    Case   control   MAF    HWE    Score                                          
  ------------------------------- ------ ------------ ----------------- -------- ------------------ ------ --------- ----- ------- ------- ------ ----- ------- ---------- ------- ----
  For rs1447295 C\>A (region1)                                                                                                                                                     
   Chan                            2013   Singapore         Asian          HB     Illumina 1M chip   180      92      17     289     94      44     5     143   **0.19**   0.957    7
   Schumacher                      2007      USA         Caucasians        PB          TaqMan        8462    2736     268   11466   10344   2472   172   12988  **0.11**   0.079    14
   Zheng                           2007      USA         Caucasians        HB          iPLEX         1169     346     31    1546     485     82     4     571   **0.08**   0.794    11
   Joung                           2012     Korea           Asian          HB          iPLEX         114      67      12     193     127     38     3     168   **0.13**   0.936    7
   Francisco                       2013     Chile        Caucasians        HB          TaqMan         56      23       4     83      16      4      1     21    **0.14**   0.309    4
   Terada                          2008     Japan           Asian          HB         PCR-RFLP       310      172     25     507     335    165    11     511   **0.18**   0.071    9
   Okobia                          2011      USA       Africa-American     HB          TaqMan        156      162     36     354     173    207    58     438   **0.37**   0.291    11
   Brankovie                       2013     Sebia        Caucasians        HB         PCR-RFLP        86      61       3     150     11      82     7     100   **0.48**   0.000    7
   Suurinirmi                      2007      USA         Caucasians        PB          TaqMan        435      136     11     582     427    107     4     538   **0.11**   0.390    15
   Zeegers                         2011      USA         Caucasians        PB          TaqMan        224      53       4     281     196     64     7     267   **0.15**   0.523    10
   Salinas                         2008      USA         Caucasians        PB          TaqMan        937      288     27    1252     994    225    14    1233   **0.10**   0.753    15
   Benford                         2010      USA       Africa-American     HB          TaqMan         86      77      26     189     237    221    65     523   **0.34**   0.000    8
   Liu                             2012     China           Asian          PB         PCR-RFLP       150      102      8     260     197     86     4     287   **0.16**   0.111    11
   Liu                             2009     Japan           Asian          HB          TaqMan        217      149     25     391     218     89    16     323   **0.19**   0.088    8
   Severi                          2007   Australian     Caucasians        PB          TaqMan        595      212     14     821     586    135    11     732   **0.11**   0.319    13
   Wokolorczyk                     2010     Poland       Caucasians        HB         PCR-RFLP       515      156     19     690     484    115     3     602   **0.10**   0.165    8
   Chen                            2009     Taiwan          Asian          PB          TaqMan        215      119      6     340     253     75     9     337   **0.14**   0.237    10
   Cheng                           2008      USA         Caucasians        HB          TaqMan        318      97       2     417     344     69     4     417   **0.09**   0.795    11
   Cheng                           2008      USA       Africa-American     HB          TaqMan         39      44       6     89      43      35    11     89    **0.32**   0.919    11
   Zheng                           2010     China           Asian          PB          iPLEX         173      96      15     284     110     35     6     151   **0.16**   0.147    12
  For rs16901979 C\>A (region2)                                                                                                                                                    
   Chan                            2013   Singapore         Asian          HB     Illumina 1M chip   139      119     31     289     64      68    12     144   **0.32**   0.302    7
   Joung                           2012     Korea           Asian          HB          iPLEX          99      81      14     194     100     57    12     169   **0.24**   0.333    7
   Okobia                          2011      USA       Africa-American     HB          TaqMan         81      158     99     338     131    193    102    426   **0.47**   0.064    11
   Chen                            2010     Taiwan          Asian          HB          TaqMan        148      148     35     331     173    138    24     335   **0.28**   0.62     11
   Benford                         2010      USA       Africa-American     HB          TaqMan         45      97      50     192     188    237    87     512   **0.40**   0.406    8
   Cheng                           2008      USA         Caucasians        HB          TaqMan        375      41       1     417     393     22     1     416   **0.03**   0.252    11
   Cheng                           2008      USA       Africa-American     HB          TaqMan         23      43      23     89      27      50    11     88    **0.41**   0.1      11
  For rs6983267 T\>G (region3)                                                                                                                                                     
   Chan                            2013   Singapore         Asian          HB     Illumina 1M chip    89      136     63     288     47      74    23     144   **0.42**   0.493    7
   Zheng                           2007      USA         Caucasians        HB          iPLEX         495      771     285   1551     142    299    132    573   **0.49**   0.293    11
   Joung                           2012     Korea           Asian          HB          iPLEX          56      92      46     194     51      86    31     168   **0.44**   0.618    7
   Francisco                       2013     Chile        Caucasians        HB          TaqMan         19      33      30     82       5      13     3     21    **0.45**   0.253    4
   Terada                          2008     Japan           Asian          HB         PCR-RFLP       211      219     77     507     206    225    80     511   **0.38**   0.94     9
   Okobia                          2011      USA       Africa-American     HB          TaqMan        307      34       2     343     373     52     1     426   **0.06**   0.562    11
   Brankovie                       2013     Sebia        Caucasians        HB         PCR-RFLP        53      80      17     150     69     129    52     250   **0.47**   0.561    7
   Salinas                         2008      USA         Caucasians        PB         PCR-RFLP       364      652     242   1258     313    617    308   1238   **0.50**   0.91     15
   Liu                             2012     China           Asian          PB         PCR-RFLP        70      137     53     260     94     137    51     282   **0.42**   0.93     11
   Liu                             2009     Japan           Asian          HB          TaqMan        151      181     59     391     147    151    25     323   **0.31**   0.104    8
   Papanikolopoulou                2011     Greece       Caucasians        HB          TaqMan         16      46      24     86      39      47    13     99    **0.37**   0.844    6
   Cheng                           2008      USA         Caucasians        HB          TaqMan         76      215     126    417     106    206    105    417   **0.50**   0.807    11
   Cheng                           2008      USA       Africa-American     HB          TaqMan         74      14       1     89      74      11     4     89    **0.11**   0.001    11
   Zheng                           2010     China           Asian          PB          iPLEX          86      134     62     282     51      72    29     152   **0.43**   0.69     12
   Penney                          2009      USA         Caucasians        PB          iPLEX         400      644     261   1305     372    707    323   1402   **0.48**   0.714    15
   Penney                          2009      USA         Caucasians        PB          iPLEX         1184    1776     812   3772     69     134    46     249   **0.45**   0.177    15

HB, Hospital based; PB, Population based; PCR-RFLP, Polymorphism chain reaction-restriction fragment length polymorphism; MAF, Minor allele frequency; HWE, Hardy-Weinberg equilibrium. WW, wild homozygous; WV, heterozygous; VV, variant homozygous.

###### Meta-analysis of the association between 8q24 rs1447295, rs16901979 and rs6983267 polymorphisms and prostate cancer risk.

  Variables                         No. of individuals   No. of studies  Homozygous          Heterozygous   Recessive           Dominant      Allele                                                                      
  -------------------------------- -------------------- ---------------- ------------------- -------------- ------------------- ------------- ------------------- ------- ------------------- ------- ------------------- -------
  rs1447295 C\>A (region1)                                                                                                                                                                                                
  All                                  20184/20439             20        1.39 (1.01--1.91)   0.000          1.26 (1.09--1.45)   0.000         0.51 (0.39--0.67)   0.001   2.46 (1.89--3.20)   0.000   1.23 (1.09--1.40)   0.000
  publication bias (Begg's test)                          *P *= 0.296    *P *= 0.382         *P *= 0.713    *P *= 0.277         *P *= 0.272                                                                               
  Ethnicity                                                                                                                                                                                                               
   Caucasion                           17288/17469             10        1.35 (0.78--2.35)   0.000          1.15 (0.92--1.44)   0.000         0.48 (0.31--0.74)   0.014   4.15 (3.26--5.28)   0.000   1.18(0.97--1.43)    0.000
   Asian                                2264/1920              7         1.87 (1.33--2.62)   0.469          1.49 (1.30--1.70)   0.112         0.38 (0.27--0.53)   0.438   1.97 (1.47--2.62)   0.000   1.44 (1.29--1.60)   0.425
   Africa-American                       632/1050              3         0.82 (0.59--1.14)   0.349          0.95 (0.77--1.18)   0.411         0.91 (0.66--1.26)   0.992   0.74 (0.43--1.29)   0.001   0.92 (0.79--1.07)   0.487
  Source of control                                                                                                                                                                                                       
   HB                                   4898/3906              12        1.28 (0.75--2.17)   0.000          1.12 (0.84--1.49)   0.000         0.52 (0.33--0.82)   0.001   2.07 (1.16--3.67)   0.000   1.16 (0.92--1.47)   0.000
   PB                                  15286/16533             8         1.80 (1.52--2.13)   0.278          1.38 (1.22--1.57)   0.000         0.44 (0.37--0.52)   0.329   3.22 (2.78--3.74)   0.000   1.34 (1.21--1.50)   0.049
  Score                                                                                                                                                                                                                   
   Low                                  2492/2391              8         1.49 (0.74--2.99)   0.000          1.17 (0.92--1.51)   0.000         0.45 (0.25--0.81)   0.003   1.79 (1.01--3.16)   0.000   1.14 (0.82--1.58)   0.000
   High                                17692/18048             12        1.32 (0.92--1.91)   0.002          1.19 (0.82--1.71)   0.003         0.54 (0.39--0.74)   0.016   3.05 (2.31--4.02)   0.000   1.29 (1.14--1.46)   0.000
  rs16901979 C\>A (region2)                                                                                                                                                                                               
  All                                   1850/2090              7         1.71 (1.36--2.16)   0.595          1.31 (1.12--1.53)   0.136         1.22 (0.80--1.87)   0.002   1.39 (1.20--1.61)   0.144   1.31 (1.18--1.46)   0.232
  publication bias (Begg's test)                          *P *= 0.609    *P *= 0.948         *P *= 0.995    *P *= 0.854         *P *= 0.689                                                                               
  Ethnicity                                                                                                                                                                                                               
   Asian                                 714/648               3         1.41 (0.95--2.09)   0.661          1.15 (0.92--1.43)   0.134         1.65 (1.13--2.41)   0.293   1.19 (0.97--1.47)   0.179   1.17 (1.00--1.38)   0.350
   Africa-American                       619/1026              3         1.91 (1.44--2.55)   0.342          1.41 (1.10--1.80)   0.385         0.96 (0.54--1.71)   0.007   1.56 (1.24--1.96)   0.413   1.40 (1.21--1.62)   0.415
  Source of control                                                                                                                                                                                                       
   HB                                   1850/2090              7         1.71 (1.36--2.16)   0.595          1.31 (1.12--1.53)   0.136         1.22 (0.80--1.87)   0.002   1.39 (1.20--1.61)   0.144   1.31 (1.18--1.46)   0.232
  Score                                                                                                                                                                                                                   
   Low                                   675/825               3         1.75 (1.22--2.51)   0.160          1.26 (0.8--1.97)    0.032         1.49 (1.08--2.05)   0.475   1.32 (0.84--2.08)   0.020   1.29 (1.10--1.52)   0.04
   High                                 1175/1265              4         1.68 (1.25--2.27)   0.826          1.34 (1.09--1.65)   0.438         1.46 (1.13--1.89)   0.548   1.42 (1.17--1.73)   0.668   1.33 (1.16--1.53)   0.585
  rs6983267 T\>G (region3)                                                                                                                                                                                                
  All                                   12233/7582             17        1.44 (1.31--1.58)   0.065          1.19 (1.10--1.29)   0.065         1.26 (1.18--1.36)   0.473   1.54 (0.93--2.57)   0.000   1.19 (1.14--1.25)   0.187
  publication bias (Begg's test)                          *P *= 0.308    *P *= 0.959         *P *= 0.072    *P *= 0.749         *P *= 0.303                                                                               
  Ethnicity                                                                                                                                                                                                               
   Caucasion                            9879/5487              9         1.47 (1.33--1.64)   0.065          1.25 (1.07--1.46)   0.027         1.27 (1.17--1.38)   0.427   1.77 (0.81--3.87)   0.000   1.21 (1.15--1.27)   0.102
   Asian                                1922/1580              6         1.33 (1.08--1.62)   0.166          1.07 (0.92--1.24)   0.746         1.27 (1.06--1.52)   0.201   1.35 (1.04--1.75)   0.005   1.14 (1.03--1.25)   0.283
  Source of control                                                                                                                                                                                                       
   HB                                   4098/3021              11        1.68 (1.30--2.16)   0.038          1.17 (1.03--1.33)   0.141         1.38 (1.22--1.55)   0.223   1.43 (1.00--2.04)   0.000   1.24 (1.15--1.33)   0.092
   PB                                   8135/4561              6         1.37 (1.22--1.54)   0.532          1.20 (1.09--1.33)   0.065         1.21 (1.10--1.32)   1.000   1.80 (0.63--5.11)   0.000   1.17 (1.10--1.24)   0.686
  Score                                                                                                                                                                                                                   
   Low                                  1698/1516              7         1.79 (1.19--2.67)   0.009          1.11 (0.94--1.30)   0.120         1.43 (1.19--1.73)   0.069   1.34 (0.98--1.84)   0.002   1.28 (1.07--1.54)   0.015
   High                                 10535/6066             10        1.42 (1.31--1.58)   0.547          1.22 (1.11--1.33)   0.121         1.24 (1.14--1.34)   0.986   1.66 (0.79--3.51)   0.000   1.19 (1.13--1.25)   0.839

HB, Hospital based; PB, Population based. OR, Odds ratio; CI, confidence interval.

###### False-positive report probability values for associations between the risk of cancer and the frequency of genotypes of 8q24 variants.

  8q24 SNP genotype                Crude OR (95%CI)     *P*[a](#t3-fn2){ref-type="fn"}  statistical power[b](#t3-fn3){ref-type="fn"}   Prior probability                                       
  -------------------------------- ------------------- -------------------------------- ---------------------------------------------- ------------------- ----------- ----------- ----------- -------
  **8q24-rs1447295 C**\>**A**                                                                                                                                                                  
  ** All patients**                                                                                                                                                                            
  **  **Homozygous                 1.39 (1.01--1.91)               \<0.0001             0.993                                          **0.000**           **0.001**   **0.010**   **0.091**   0.502
  **  **Heterozygous               1.26 (1.09--1.45)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Recessive                  0.51 (0.39--0.67)               \<0.0001             0.896                                          **0.000**           **0.001**   **0.011**   **0.100**   0.527
  **  **Dominant                   2.46 (1.89--3.20)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Allele comparision         1.23 (1.09--1.40)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Ethnicity-Caucasian                                                                                                                                                                     
  **  **Recessive                  0.48 (0.31--0.74)               \<0.0001             0.472                                          **0.001**           **0.002**   **0.021**   **0.175**   0.680
  **  **Dominant                   4.15 (3.26--5.28)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Ethnicity-Asian                                                                                                                                                                         
  **  **Homozygous                 1.87 (1.33--2.62)               \<0.0001             0.059                                          **0.005**           **0.015**   **0.144**   0.630       0.944
  **  **Heterozygous               1.49 (1.30--1.70)               \<0.0001             0.986                                          **0.000**           **0.001**   **0.010**   0.092       0.504
  **  **Recessive                  0.38 (0.27--0.53)               \<0.0001             0.028                                          **0.011**           **0.031**   0.262       0.781       0.973
  **  **Dominant                   1.97 (1.47--2.62)               \<0.0001             0.968                                          **0.000**           **0.001**   **0.010**   **0.094**   0.508
  **  **Allele comparision         1.44 (1.29--1.60)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Source of control-HB                                                                                                                                                                    
  **  **Recessive                  0.52 (0.33--0.82)                0.0436              0.948                                          **0.121**           0.293       0.820       0.979       0.998
  **  **Dominant                   2.07 (1.16--3.67)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Source of control-PB                                                                                                                                                                    
  **  **Homozygous                 1.80 (1.52--2.13)               \<0.0001             0.772                                          **0.000**           **0.001**   **0.013**   **0.115**   0.564
  **  **Heterozygous               1.38 (1.22--1.57)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Recessive                  0.44 (0.37--0.52)               \<0.0001             0.440                                          **0.001**           **0.002**   **0.022**   **0.185**   0.694
  **  **Dominant                   3.22 (2.78--3.74)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Allele comparision         1.34 (1.21--1.50)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Score-Low                                                                                                                                                                               
  **  **Recessive                  0.45 (0.25--0.81)               \<0.0001             0.114                                          **0.003**           **0.008**   **0.080**   0.467       0.898
  **  **Dominant                   1.79 (1.01--3.16)               \<0.0001             0.995                                          **0.000**           **0.001**   **0.010**   **0.091**   0.501
  ** **Score-High                                                                                                                                                                              
  **  **Recessive                  0.54 (0.39--0.74)               \<0.0001             0.696                                          **0.000**           **0.001**   **0.014**   **0.126**   0.590
  **  **Dominant                   3.05 (2.31--4.02)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Allele comparision         1.29 (1.14--1.46)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **8q24-rs16901979 C**\>**A**                                                                                                                                                                 
  ** All patients**                                                                                                                                                                            
  **  **Homozygous                 1.71 (1.36--2.16)                0.0663              0.995                                          **0.167**           0.375       0.868       0.985       0.999
  **  **Heterozygous               1.31 (1.12--1.53)                0.3859              1.000                                          0.537               0.776       0.974       0.997       1.000
  **  **Dominant                   1.39 (1.20--1.61)                0.1506              0.999                                          0.312               0.576       0.937       0.993       0.999
  **  **Allele comparision         1.31 (1.18--1.46)                0.0524              1.000                                          0.136               0.320       0.838       0.981       0.998
  ** **Ethnicity-Asian                                                                                                                                                                         
  **  **Recessive                  1.65 (1.13--2.41)                0.3859              0.908                                          0.560               0.793       0.977       0.998       1.000
  **  **Allele comparision         1.17 (1.00--1.38)                0.0394              0.999                                          **0.106**           0.262       0.796       0.975       0.997
  ** **Ethnicity-Africa-American                                                                                                                                                               
  **  **Homozygous                 1.91 (1.44--2.55)               \<0.0001             0.902                                          **0.116**           0.282       0.812       0.978       0.998
  **  **Heterozygous               1.41 (1.10--1.80)                0.0028              0.837                                          **0.010**           **0.029**   0.249       0.770       0.971
  **  **Dominant                   1.56 (1.24--1.96)               \<0.0001             0.375                                          **0.001**           **0.002**   **0.026**   0.210       0.727
  **  **Allele comparision         1.40 (1.21--1.62)               \<0.0001             0.371                                          **0.001**           **0.002**   **0.026**   0.212       0.730
  ** **Source of control-HB                                                                                                                                                                    
  **  **All patients                                                                                                                                                                           
  **  **Homozygous                 1.71 (1.36--2.16)                0.0663              0.995                                          **0.167**           0.375       0.868       0.985       0.999
  **  **Heterozygous               1.31 (1.12--1.53)                0.3859              1.000                                          0.537               0.776       0.974       0.997       1.000
  **  **Dominant                   1.39 (1.20--1.61)                0.1506              1.000                                          0.311               0.575       0.937       0.993       0.999
  **  **Allele comparision         1.31 (1.18--1.46)                0.0524              1.000                                          **0.136**           0.320       0.838       0.981       0.998
  ** **Score-Low                                                                                                                                                                               
  **  **Homozygous                 1.75 (1.22--2.51)                0.6976              0.993                                          0.678               0.863       0.986       0.999       1.000
  **  **Recessive                  1.49 (1.08--2.05)                0.7287              0.994                                          0.687               0.868       0.986       0.999       1.000
  **  **Allele comparision         1.29 (1.10--1.52)                0.6989              1.000                                          0.677               0.863       0.986       0.999       1.000
  ** **Score-High                                                                                                                                                                              
  **  **Homozygous                 1.68 (1.25--2.27)                0.0297              0.883                                          **0.092**           0.232       0.769       0.971       0.997
  **  **Heterozygous               1.34 (1.09--1.65)                0.2149              1.000                                          0.392               0.659       0.955       0.995       1.000
  **  **Recessive                  1.46 (1.13--1.89)                0.0551              0.926                                          **0.151**           0.349       0.855       0.983       0.998
  **  **Dominant                   1.42 (1.17--1.73)                0.0546              0.999                                          **0.141**           0.330       0.844       0.982       0.998
  **  **Allele comparision         1.33 (1.16--1.53)                0.0131              1.000                                          **0.038**           **0.105**   0.565       0.929       0.992
  **8q24-rs6983267 T**\>**G**                                                                                                                                                                  
  ** All patients**                                                                                                                                                                            
  **  **Homozygous                 1.44 (1.31--1.58)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Heterozygous               1.19 (1.10--1.29)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Recessive                  1.26 (1.18--1.36)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Allele comparision         1.19 (1.14--1.25)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Ethnicity-Caucasian                                                                                                                                                                     
  **  **Homozygous                 1.47 (1.33--1.64)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Heterozygous               1.25 (1.07--1.46)                0.0001              1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Recessive                  1.27 (1.17--1.38)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Allele comparision         1.21 (1.15--1.27)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Ethnicity-Aasian                                                                                                                                                                        
  **  **Homozygous                 1.33 (1.08--1.62)                0.0026              0.939                                          **0.008**           **0.024**   0.215       0.734       0.965
  **  **Recessive                  1.27 (1.06--1.52)                0.0048              0.959                                          **0.015**           **0.043**   0.331       0.833       0.980
  **  **Dominant                   1.35 (1.04--1.75)                0.0477              1.000                                          **0.125**           0.300       0.825       0.979       0.998
  **  **Allele comparision         1.14 (1.03--1.25)                0.0038              1.000                                          **0.011**           **0.033**   0.273       0.792       0.974
  ** **Source of control-HB                                                                                                                                                                    
  **  **Homozygous                 1.68 (1.30--2.16)                0.001               1.000                                          **0.003**           **0.009**   **0.090**   0.500       0.909
  **  **Heterozygous               1.17 (1.03--1.33)                0.002               1.000                                          **0.006**           **0.018**   **0.165**   0.666       0.952
  **  **Recessive                  1.38 (1.22--1.55)                0.0755              1.000                                          **0.185**           0.405       0.882       0.987       0.999
  **  **Dominant                   1.43 (1.00--2.04)                0.0004              1.000                                          **0.001**           **0.004**   **0.038**   0.286       0.800
  **  **Allele comparision         1.24 (1.15--1.33)                0.0009              1.000                                          **0.003**           **0.008**   **0.082**   0.473       0.900
  ** **Source of control-PB                                                                                                                                                                    
  **  **Homozygous                 1.37 (1.22--1.54)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Heterozygous               1.20 (1.09--1.33)                0.0021              1.000                                          **0.006**           **0.019**   **0.172**   0.677       0.955
  **  **Recessive                  1.21 (1.10--1.32)               \<0.0001             1.000                                          **0.006**           **0.019**   **0.172**   0.677       0.955
  **  **Allele comparision         1.17 (1.10--1.24)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  ** **Score-Low                                                                                                                                                                               
  **  **Homozygous                 1.79 (1.19--2.67)                0.0008              0.871                                          **0.003**           **0.008**   **0.083**   0.478       0.902
  **  **Recessive                  1.43 (1.19--1.73)                0.0007              0.863                                          **0.002**           **0.007**   **0.074**   0.448       0.890
  **  **Allele comparision         1.28 (1.07--1.54)                0.0016              1.000                                          **0.005**           **0.014**   **0.137**   0.615       0.941
  ** **Score-High                                                                                                                                                                              
  **  **Homozygous                 1.42 (1.31--1.58)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500
  **  **Heterozygous               1.22 (1.11--1.33)                0.0003              1.000                                          **0.001**           **0.003**   **0.029**   0.231       0.710
  **  **Recessive                  1.24 (1.14--1.34)                0.0034              1.000                                          **0.010**           **0.030**   0.252       0.773       0.971
  **  **Allele comparision         1.19 (1.13--1.25)               \<0.0001             1.000                                          **0.000**           **0.001**   **0.010**   **0.091**   0.500

OR, Odds ratio; CI, Confidence interval. The results in false-positive report probability analysis were in bold, if the prior probability \<0.2.

^a^Chi-square test was used to calculate the genotype frequency distributions.

^b^Statistical power was calculated using the number of observations in the subgroup and the OR and P values in this table.

[^1]: These authors contributed equally to this work.
